Picture of Auxly Cannabis logo

XLY — Auxly Cannabis News Story

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSuper Stock

Canada's Auxly Q4 revenue rises on higher volumes and pricing

Overview

Canada cannabis CPG firm's Q4 revenue grew 16% yr/yr

Adjusted EBITDA for Q4 rose 14% yr/yr

Net income for Q4 declined due to realized fair value losses on inventory

Outlook

Auxly plans C$10-12 mln capital investment at Auxly Leamington in 2026

Company expects Canadian cannabis market to benefit from rising social acceptability and illicit market share gains

Auxly is actively evaluating international export opportunities and plans investment in export capabilities in 2026

Result Drivers

HIGHER VOLUMES AND PRICING - Q4 revenue growth was driven by increased volume and pricing across dried flower, pre-roll and vape products

OPERATIONAL IMPROVEMENTS - Gross margin benefited from favorable production costs at Auxly Leamington and operational improvements in cultivation and manufacturing

HIGHER SG&A - SG&A expenses increased due to investments to support higher sales

Company press release: ID:nCNWkGMJFa

Key Details

MetricBeat/MissActualConsensus Estimate
Q4 RevenueMissC$40.10 mlnC$40.90 mln (1 Analyst)
Q4 Net IncomeC$900,000
Q4 Adjusted EBITDAC$12.50 mln
Analyst Coverage The one available analyst rating on the shares is "buy" The average consensus recommendation for the pharmaceuticals peer group is "buy" Wall Street's median 12-month price target for Auxly Cannabis Group Inc is C$0.25, about 72.4% above its March 25 closing price of C$0.15 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Auxly Cannabis

See all news